Association between CDAI change over time and self-reported depression over 2 years of followup using general estimating equation.
| Variables | Unadjusted OR (95% CI) | Adjusted OR (95% CI), Model 1* | Adjusted OR (95% CI), Model 2** |
|---|---|---|---|
| CDAI over time | 1.01 (1.00–1.01) | 1.01 (1.00–1.01) | – |
| CDAI category over time | |||
| Remission or LDA | Ref | – | Ref |
| MDA | 1.14 (1.06–1.22) | – | 1.14 (1.04–1.26) |
| HDA | 1.26 (1.13–1.41) | – | 1.26 (1.12–1.42) |
| CDAI binary over time | |||
| Remission or LDA | Ref | – | Ref |
| MDA or HDA | 1.18 (1.10–1.27) | – | 1.22 (1.10–1.35) |
| Covariates | |||
| Female sex | 1.88 (1.15–3.08) | 1.93 (1.15–3.25) | – |
| No. comorbidities | 1.53 (1.39–1.70) | 1.32 (1.19–1.47) | – |
| Positive RF | 0.60 (0.39–0.92) | 0.79 (0.50–1.26) | – |
| Fatigue score (0–10) | 1.19 (1.11–1.28) | 1.14 (1.05–1.24) | |
| Prior use of csDMARD | 0.52 (0.34–0.80) | 0.74 (0.46–1.19) | |
| Prior use of bDMARD | 0.43 (0.19–0.95) | 0.53 (0.19–1.49) | – |
| Current use and route of bDMARD | – | ||
| Infusion | 1.01 (1.00–1.03) | 0.95 (0.76–1.19) | – |
| Subcutaneous | 1.10 (0.97–1.25) | 1.31 (1.06–1.63) |
Values in bold face are statistically significant.
↵* Model 1: adjusted for sex, positive RF, prior use of csDMARD and bDMARD, current bDMARD administration route, total number of bDMARD, number of comorbidities, and fatigue score.
↵** Model 2: CDAI category and binary variables adjusted for the relevant covariates (OR for these covariates are not shown in the table). CDAI: clinical disease activity index; LDA: low disease activity; MDA: medium disease activity; HDA: high disease activity; RF: rheumatoid factor; csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biologic DMARD.